B

BioLine RX Ltd
NASDAQ:BLRX

Watchlist Manager
BioLine RX Ltd
NASDAQ:BLRX
Watchlist
Price: 2.8 USD 1.08% Market Closed
Market Cap: 223.8m USD

Operating Margin
BioLine RX Ltd

-88.9%
Current
-155%
Average
-4.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-88.9%
=
Operating Profit
-11.3m
/
Revenue
12.7m

Operating Margin Across Competitors

No Stocks Found

BioLine RX Ltd
Glance View

Market Cap
223.8m USD
Industry
Biotechnology

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

BLRX Intrinsic Value
6.91 USD
Undervaluation 59%
Intrinsic Value
Price
B
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-88.9%
=
Operating Profit
-11.3m
/
Revenue
12.7m
What is the Operating Margin of BioLine RX Ltd?

Based on BioLine RX Ltd's most recent financial statements, the company has Operating Margin of -88.9%.

Back to Top